Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients

Author:

Danthu Clément,Hantz SébastienORCID,Dahlem Arthur,Duval Marion,Ba Bacary,Guibbert Manon,El Ouafi Zhour,Ponsard Séverine,Berrahal Insaf,Achard Jean-Michel,Bocquentin Frédérique,Allot Vincent,Rerolle Jean-Philippe,Alain Sophie,Touré Fatouma

Abstract

BackgroundKidney transplant recipients and patients receiving hemodialysis are immunocompromised populations that are prioritized for COVID-19 vaccination but were excluded from clinical trials of SARS-CoV-2 mRNA vaccines. Antibody titers and rates of seroconversion after vaccination are lower among patients with CKD and those taking immunosuppressants compared with controls. Data are lacking regarding their humoral response to vaccination to prevent COVID-19.MethodsThis investigation of early serological response after COVID-19 vaccination with the Pfizer/BioNTech (BNT162b2) mRNA vaccine included 78 patients undergoing hemodialysis, 74 kidney transplant recipients, and seven healthy controls. We recorded data from the medical file for various clinical parameters, including response to hepatitis B vaccination, and measured antibody titers against SARS-CoV-2 at 0, 14, 28, 36, and 58 days after the first injection.ResultsIn controls, we detected antibodies at a positive level (>13 arbitrary units per ml; AU/ml) at day 14 postinjection, which increased progressively to peak at day 36 (1082 AU/ml; interquartile range [IQR], 735.0–1662.0). Patients undergoing hemodialysis had lower titers that peaked at day 58 (276 AU/ml; IQR, 83.4–526.0). We detected a positive antibody level in only three transplant recipients at day 36. In patients on hemodialysis, those aged <75 years had a higher antibody response versus those aged >75 years, and serum albumin and Kt/V were positively correlated with serological response (P<0.04 and P<0.0, respectively); nonresponders to HBV vaccine had the lowest anti–SARS-CoV-2 antibody titers.ConclusionsOur results suggest that the postvaccination humoral response is strongly inhibited by immunosuppressant therapy in kidney transplant recipients, and is reduced by the uremic condition in patients undergoing hemodialysis.

Publisher

American Society of Nephrology (ASN)

Subject

Nephrology,General Medicine

Reference19 articles.

1. Kronbichler A , Anders HJ , Fernandez-Juárez GM , Floege J , Goumenos D , Segelmark M , .; Immunonephrology Working Group of the ERA-EDTA (European Renal Association – European Dialysis, Transplant Association): Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases [published online ahead of print March 9, 2021]. Nephrol Dial Transplant

2. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

3. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

4. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults;Mulligan;Nature,2020

5. Practical guide to vaccination in all stages of CKD, including patients treated by dialysis or kidney transplantation;Krueger;Am J Kidney Dis,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3